Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development

被引：134

作者：

Costa, Ricardo ^{[1
]}

Shah, Ami N. ^{[3
]}

Santa-Maria, Cesar A. ^{[1
,2
]}

Cruz, Marcelo R. ^{[1
]}

Mahalingam, Devalingam ^{[4
,5
,6
]}

Carneiro, Benedito A. ^{[1
,2
]}

Chae, Young Kwang ^{[1
,2
]}

Cristofanilli, Massimo ^{[1
,2
]}

Gradishar, William J. ^{[1
,2
]}

Giles, Francis J. ^{[1
,2
]}

机构：

[1] Feinberg Sch Med, Div Hematol Oncol, Dev Therapeut Program, Chicago, IL USA

[2] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[3] Feinberg Sch Med, Div Hematol Oncol, Chicago, IL USA

[4] Univ Texas Hlth Sci Ctr San Antonio, Dept Med Canc Res, San Antonio, TX 78229 USA

[5] Univ Texas Hlth Sci Ctr San Antonio, Therapy Ctr, San Antonio, TX 78229 USA

[6] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, San Antonio, TX 78229 USA

来源：

CANCER TREATMENT REVIEWS | 2017年 / 53卷

关键词：

Triple negative breast cancer; Epidermal Growth Factor Receptor; Targeted therapy; mTOR; CELL LUNG-CANCER; IXABEPILONE PLUS CAPECITABINE; PATHOLOGICAL COMPLETE RESPONSE; MONOCLONAL-ANTIBODY CETUXIMAB; RANDOMIZED PHASE-II; 1ST-LINE TREATMENT; OPEN-LABEL; PROTEIN EXPRESSION; CLINICAL-PRACTICE; SPORADIC BREAST;

D O I：

10.1016/j.ctrv.2016.12.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple negative breast cancer (TNBC) accounts for 10-20% of cases in breast cancer. Despite recent advances in the treatment of hormonal receptor+ and HER2+ breast cancers, there are no targeted therapies available for TNBC. Evidence supports that most patients with TNBC express the transmembrane Epidermal Growth Factor Receptor (EGFR). However, early phase clinical trials failed to demonstrate significant activity of EGFR-targeted monoclonal antibodies and/or tyrosine kinase inhibitors. Here, we review the recent discoveries related to the underlying biology of the EGFR pathway in TNBC, clinical progress to date and suggest rational future approaches for investigational therapies in TNBC. (C) 2017 Elsevier Ltd. All rights reserved.

引用

页码：111 / 119

页数：9

共 113 条

[41] Lapatinib plus capecitabine for HER2-positive advanced breast cancer [J].

Geyer, Charles E. ;

Forster, John ;

Lindquist, Deborah ;

Chan, Stephen ;

Romieu, C. Gilles ;

Pienkowski, Tadeusz ;

Jagiello-Gruszfeld, Agnieszka ;

Crown, John ;

Chan, Arlene ;

Kaufman, Bella ;

Skarlos, Dimosthenis ;

Campone, Mario ;

Davidson, Neville ;

Berger, Mark ;

Oliva, Cristina ;

Rubin, Stephen D. ;

Stein, Steven ;

Cameron, David .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (26) :2733-2743

[42]

GIORDANO SB, 2013, SAN ANT BREAST CANC

[43] ABT-414 in patients with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR). [J].

Goss, Glenwood D. ;

Vokes, Everett E. ;

Gordon, Michael S. ;

Gandhi, Leena ;

Papadopoulos, Kyriakos P. ;

Rasco, Drew Warren ;

Pedersen, Michelle ;

Fischer, Judee S. ;

Chu, Katharine ;

Ames, William ;

Xiong, Hao ;

Lee, Ho-Jin ;

Zeng, Jiewei ;

Roberts-Rapp, Lisa ;

Ansell, Peter ;

Reilly, Ed ;

Holen, Kyle D. ;

Tolcher, Anthony W. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[44] ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling [J].

GrausPorta, D ;

Beerli, RR ;

Daly, JM ;

Hynes, NE .

EMBO JOURNAL, 1997, 16 (07) :1647-1655

[45] Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma [J].

Green, Michael R. ;

Monti, Stefano ;

Rodig, Scott J. ;

Juszczynski, Przemyslaw ;

Currie, Treeve ;

O'Donnell, Evan ;

Chapuy, Bjoern ;

Takeyama, Kunihiko ;

Neuberg, Donna ;

Golub, Todd R. ;

Kutok, Jeffery L. ;

Shipp, Margaret A. .

BLOOD, 2010, 116 (17) :3268-3277

[46] Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors [J].

Guarneri, V ;

Broglio, K ;

Kau, SW ;

Cristofanilli, M ;

Buzdar, AU ;

Valero, V ;

Buchholz, T ;

Meric, F ;

Middleton, L ;

Hortobagyi, GN ;

Gonzalez-Angulo, AM .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1037-1044

[47] INSECT CELL-EXPRESSED P180(ERBB3) POSSESSES AN IMPAIRED TYROSINE KINASE-ACTIVITY [J].

GUY, PM ;

PLATKO, JV ;

CANTLEY, LC ;

CERIONE, RA ;

CARRAWAY, KL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (17) :8132-8136

[48]

Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, P907, DOI [10.1200/JCO.2009.25.6529, 10.1200/JOP.777003, 10.5858/134.6.907]

[49] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial [J].

Heinemann, Volker ;

von Weikersthal, Ludwig Fischer ;

Decker, Thomas ;

Kiani, Alexander ;

Vehling-Kaiser, Ursula ;

Al-Batran, Salah-Eddin ;

Heintges, Tobias ;

Lerchenmueller, Christian ;

Kahl, Christoph ;

Seipelt, Gernot ;

Kullmann, Frank ;

Stauch, Martina ;

Scheithauer, Werner ;

Hielscher, Joerg ;

Scholz, Michael ;

Mueller, Sebastian ;

Link, Hartmut ;

Niederle, Norbert ;

Rost, Andreas ;

Hoeffkes, Heinz-Gert ;

Moehler, Markus ;

Lindig, Reinhard U. ;

Modest, Dominik P. ;

Rossius, Lisa ;

Kirchner, Thomas ;

Jung, Andreas ;

Stintzing, Sebastian .

LANCET ONCOLOGY, 2014, 15 (10) :1065-1075

[50]

HERBST RS, 2015, LANCET

← 1 2 3 4 5 6 7 8 9 10 →